Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

These upgrades include new typography, materials, and 3D features that expand motion design and visual storytelling. It ...

Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

Ludovic Orlando's Horses is an enthralling account by one of the main players, detailing how genetics has rewritten what we ...

New genetic evidence reveals unexpected killers behind one of history’s deadliest military disasters.

Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...

As habitats and hosts keep vanishing, the bloodsuckers are turning to us for a free meal.

GENE202 is a single dose gene therapy for patients with rare metabolic disease, methylmalonic acidaemia.

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

In Regents of the University of California v. Broad Institute, Inc., the Federal Circuit addressed the issue of conception and reduction to ...

Advancements in AI, multi-omics, and genome editing are transforming life sciences and biotechnology, addressing new ...